Literature DB >> 12127554

Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity.

Roberto P Falcão1, Aglair B Garcia, Maria G Marques, Belinda P Simões, Benedito A Fonseca, Miriam L Rodrigues, Norma T Foss.   

Abstract

We report the findings of three new cases of a distinct clinicopathologic natural killer (NK) cell malignancy characterized by cutaneous, nodal and bone marrow infiltration by CD3-CD4+CD56+ NK blastic cells. Tumor cells were detected in bone marrow and in peripheral blood smears and showed finely distributed nuclear chromatin with nucleoli and a moderate amount of cytoplasm. Epstein-Barr virus (EBV) DNA was negative in the two tested cases. The immunophenotypes determined by flow cytometry were identical concerning mCD3-cytCD3-CD4+weakCD56+ HLA-DR+. The TCR was in germline configuration in the two cases tested. NK cell activity was demonstrated only in one out of the two cases tested. The negative reactions with alpha-naphthyl-acetate-esterase (ANAE), CD11b and CD14 strongly suggested that the tumor cells were not of the monocytic lineage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127554     DOI: 10.1016/s0145-2126(02)00014-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.

Authors:  Karen D Wright; Mihaela M Onciu; Elaine Coustan-Smith; Dario Campana; Susana C Raimondi; Hiroto Inaba; Raul Ribeiro; Ching-Hon Pui; John T Sandlund
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

2.  Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications.

Authors:  Armin G Jegalian; Nataliya P Buxbaum; Fabio Facchetti; Mark Raffeld; Stefania Pittaluga; Alan S Wayne; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.